Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, and colleagues wrote. “Alopecia areata (AA) is a chronic, relapsing autoimmune disorder with an approximate 2% lifetime incidence among patients in the United States, affecting both adult and pediatric populations, and it has no sex predilection,” Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Patients with alopecia areata who were treated with ritlecitinib or brepocitinib had significant downregulation of immune biomarkers, according to a biopsy sub-study. If you continue to have this issue please contact. Please provide your email address to receive an email when new articles are posted on. Receive an email when new articles are posted on Please see the study for all other authors’ relevant financial disclosures. JAK inhibitors could improve alopecia areataĭisclosures: Guttman-Yassky reports financial relationships with AbbVie, Allergan, Amgen, Asana Biosciences, Celgene, Concert, Dermavant, Dermira, DS Biopharma, Eli Lilly, EMD Serono, Escalier, FLX Bio, Galderma, Glenmark, Innovaderm, Janssen, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Novan, Novartis, Pfizer, Regeneron, Relexar, Sanofi and Union Therapeutics and Relexar.